That was Hospira, but I doubt they are the partner. OTOH, they have as little oligosaccharide characterization capability as most entities, so why not?
Maybe that is the partner and Teva was not interested in that formulation?
Teva’s Lovenox partner is not HSP. Moreover, the word partner probably gives Teva more credit than it deserves; as far as I know, Teva did none of the Lovenox development work and is merely the regulatory and (prospective) distribution arm for the other company’s product.